Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ARIAD Exercises Ridaforolimus Option | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ARIAD Exercises Ridaforolimus Option

ARIAD Pharmaceuticals, Inc. has exercised its option with Merck & Co. to co-promote ridaforolimus, an investigational mTOR inhibitor, in the sarcoma indication, upon approval in the U.S.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ARIAD Pharmaceuticals, Inc. has exercised its option with Merck & Co. to co-promote ridaforolimus, an investigational mTOR inhibitor, in the sarcoma indication, upon approval in the U.S.

Under the license agreement dating back to May 2010 for the development, manufacture and commercialization of ridaforolimus in oncology, ARIAD has the option to co-promote ridaforolimus with as much as 20% of the sales effort for the product in all indications in the U.S.

“The decision to co-promote ridaforolimus upon potential launch in 2012 is consistent with our plans to build a fully integrated commercial oncology company and dovetails with the potential launch of ponatinib, our investigational pan-BCR-ABL inhibitor, in patients with resistant or intolerant chronic myeloid leukemia in late 2012 or early 2013,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters